Send to

Choose Destination
See comment in PubMed Commons below
Hepatology. 2015 Aug;62(2):567-74. doi: 10.1002/hep.27709. Epub 2015 Feb 13.

Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.

Author information

  • 1Department of Medicine, DIMED, Padua, Italy.
  • 2Division of Gastroenterology and Hepatology, Mayo Clinic, College of Medicine, Rochester, MN.
  • 3Department of Clinical Medicine, "Sapienza" University of Rome, Rome, Italy.
  • 4Internal Medicine, University of Udine, Udine, Italy.
  • 5IRCCS Hospital, University of Milan, Milan, Italy.
  • 6Department of Clinical Medicine, University of Bologna, Bologna, Italy.
  • 7Internal Medicine, University of Florence, Florence, Italy.
  • 8General Hospital of Omegna (Verbania), Verbania, Italy.
  • 9Hospital Giovanni XXIII of Monastier di Treviso, Treviso, Italy.
  • 10General Hospital of Comiso (Ragusa), Ragusa, Italy.
  • 11Unit of Hepatic Emergencies and Liver Transplantation, University of Padua, Padua, Italy.


Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment. Terlipressin with albumin is effective in the reversal of HRS. Where terlipressin is not available, as in the United States, midodrine and octreotide with albumin are used as an alternative treatment of HRS. The aim was to compare the effectiveness of terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of HRS in a randomized controlled trial. Twenty-seven patients were randomized to receive terlipressin with albumin (TERLI group) and 22 to receive midodrine and octreotide plus albumin (MID/OCT group). The TERLI group received terlipressin by intravenous infusion, initially 3 mg/24 hours, progressively increased to 12 mg/24 hours if there was no response. The MID/OCT group received midodrine orally at an initial dose of 7.5 mg thrice daily, with the dose increased to a maximum of 12.5 mg thrice daily, together with octreotide subcutaneously: initial dose 100 μg thrice daily and up to 200 μg thrice daily. Both groups received albumin intravenously 1 g/kg of body weight on day 1 and 20-40 g/day thereafter. There was a significantly higher rate of recovery of renal function in the TERLI group (19/27, 70.4%) compared to the MID/OCT group (6/21, 28.6%), P = 0.01. Improvement in renal function and lower baseline Model for End-Stage Liver Disease score were associated with better survival.


Terlipressin plus albumin is significantly more effective than midodrine and octreotide plus albumin in improving renal function in patients with HRS.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center